Christina Patterson
Physician Assistant · York, PANPI 1821026121
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $46,178 of the $59,513 with a category attached, or 77.6%. 35 manufacturers reported payments, led by AbbVie at 24.1% of the total. Among physician assistant clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 220 payments — averaging $270.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$14K
- Pharmacyclics LLC, An Abbvie Company$13K
- AstraZeneca$10K
- Exelixis Inc.$5K
- Dova Pharmaceuticals$4K
- Mirati Therapeutics, Inc.$3K
- plus $10K from 29 others
What the payments were for
- Consulting fees$4,9978%
- Speaking & faculty fees$46,17878%
- Travel & lodging$3,6586%
- Food & beverage$3,9547%
- Education$7271%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 47 | $14,342 |
| Pharmacyclics LLC, An Abbvie Company | 32 | $12,924 |
| AstraZeneca(2 entities) | 31 | $10,471 |
| Exelixis Inc. | 8 | $4,674 |
| Dova Pharmaceuticals | 6 | $3,814 |
| Mirati Therapeutics, Inc. | 6 | $3,250 |
| Seagen Inc. | 13 | $3,089 |
| Johnson & Johnson(2 entities) | 13 | $2,901 |
| GSK | 6 | $1,122 |
| Sanofi | 8 | $844 |
| Bristol Myers Squibb | 4 | $661 |
| AVEO Pharmaceuticals, Inc. | 4 | $384 |
| Astellas Pharma US Inc | 7 | $384 |
| Genentech USA, Inc. | 5 | $135 |
| Sobi, Inc | 1 | $100 |
| Array Biopharma Inc | 5 | $53 |
| Fresenius Kabi USA, LLC | 2 | $48 |
| US Oncology Corporate, Inc. | 1 | $37 |
| Global Blood Therapeutics, Inc. | 2 | $26 |
| Beigene USA, Inc. | 1 | $25 |
| Bayer | 2 | $24 |
| Tersera Therapeutics LLC | 2 | $24 |
| Rigel Pharmaceuticals, Inc. | 2 | $21 |
| Morphosys, US Inc. | 1 | $19 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Novartis | 1 | $14 |
| ADC Therapeutics America, Inc. | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| EMD Serono, Inc. | 1 | $12 |
| Acrotech Biopharma Inc. | 1 | $12 |
| Epizyme, Inc. | 1 | $12 |
| Janssen Scientific Affairs, LLC | 1 | $11 |
| Iovance Biotherapeutics, Inc. | 1 | $10 |
| Pfizer | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$59,513 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 82 | $1,228,014 |
| ImbruvicaIbrutinib | 71 | $1,151,915 |
| XtandiEnzalutamide | 73 | $988,836 |
| Lenalidomide | 58 | $805,770 |
| BrukinsaZanubrutinib | 49 | $729,911 |
| VerzenioAbemaciclib | 43 | $646,252 |
| JaypircaPirtobrutinib | 27 | $585,193 |
| IbrancePalbociclib | 37 | $564,970 |
| JakafiRuxolitinib Phosphate | 32 | $547,537 |
| NubeqaDarolutamide | 39 | $513,339 |
| PromactaEltrombopag Olamine | 31 | $443,882 |
| IclusigPonatinib Hcl | 20 | $434,826 |
| BraftoviEncorafenib | 27 | $416,627 |
| KisqaliRibociclib Succinate | 34 | $381,744 |
| RevlimidLenalidomide | 27 | $363,822 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $10,471 | $1,484,09398 claims |
| Lilly USA, LLCVerzenio, Jaypirca | $17 | $1,231,44570 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $12,924 | $1,151,91571 claims |
| Astellas Pharma US IncXtandi | $384 | $988,83673 claims |
| NovartisPromacta, Kisqali | $14 | $825,62665 claims |
| Beigene USA, Inc.Brukinsa | $25 | $729,91149 claims |
| Array Biopharma IncBraftovi, Mektovi | $53 | $702,15550 claims |
| PfizerIbrance | $9 | $564,97037 claims |
| BayerNubeqa | $24 | $513,33939 claims |
| Bristol Myers SquibbRevlimid | $661 | $363,82227 claims |
| Exelixis Inc.Cabometyx | $4,674 | $306,13612 claims |
| AbbVieVenclexta | $14,342 | $305,02230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Other physician assistant in York
- Erin CrownState College$1.2M
- Tricia BootsCranberry Twp$313K
- Melissa FerrariPhiladelphia$223K
- Jason OberdickWexford$206K
- Justine RobertsMurrysville$173K
- Allison BoydErie$163K
- Joshua TrbovichWashington$144K
- Daniel TelegaErie$124K
- Jeffrey CameronWashington$89K
- Dorissa BrivchikPittsburgh$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.